Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Overview of attention for article published in Frontiers in Pharmacology, February 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,807 followers.

New Research: Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis https://t.co/NWXnE9jAAa #pharmacology

09 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.